Libtayo 350 mg/7 mL (50 mg/mL) injection Images
Generic Name: cemiplimab
This medication has been identified as Libtayo 350 mg/7 mL (50 mg/mL) injection. It is supplied by Regeneron Pharmaceuticals, Inc.
Libtayo is used in the treatment of Squamous Cell Carcinoma; Basal Cell Carcinoma; Non Small Cell Lung Cancer and belongs to the drug class anti-PD-1 and PD-L1 monoclonal antibodies (immune checkpoint inhibitors). Libtayo 350 mg/7 mL (50 mg/mL) injection is not a controlled substance under the Controlled Substances Act (CSA).
Images of medication
Libtayo
- Generic Name
- cemiplimab
- Strength
- 350 mg/7 mL (50 mg/mL) injection
- Availability
- Prescription only
- Drug Class
- Anti-PD-1 and PD-L1 monoclonal antibodies (immune checkpoint inhibitors)
- CSA Schedule
- Not a controlled drug
- Labeler / Supplier
- Regeneron Pharmaceuticals, Inc.
- National Drug Code (NDC)
- 61755-0008
More about Libtayo (cemiplimab)
- Check interactions
- Compare alternatives
- Pricing & coupons
- Reviews (6)
- Drug images
- Side effects
- Dosage information
- During pregnancy
- FDA approval history
- Drug class: anti-PD-1 and PD-L1 monoclonal antibodies (immune checkpoint inhibitors)
- Breastfeeding
- En español
Patient resources
Professional resources
Related treatment guides
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
